NCNA - ニュ―カナ (NuCana plc)

NCNAのニュース

   NuCana to Participate in the 2022 Jefferies Healthcare Conference  2022/06/01 20:01:00 GlobeNewswire
EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Jefferies Healthcare Conference.
   Investors Focused Stock: Aeterna Zentaris Inc. (NASDAQ:AEZS), NuCana plc (NASDAQ:NCNA)  2022/03/24 01:41:26 Stock Equity
Aeterna Zentaris Inc. (NASDAQ:AEZS) with the stream of -1.07% also noticed, India NuCana plc (NASDAQ:NCNA) encountered a rapid change of -2.97% in the last hour of Wednesday’s trading session. Aeterna … The post Investors Focused Stock: Aeterna Zentaris Inc. (NASDAQ:AEZS), NuCana plc (NASDAQ:NCNA) appeared first on Stocks Equity .
   NuCana plc (NASDAQ: NCNA) Drops -15.35 Percent In Recent Session, Why Are You Interested?  2022/03/08 16:00:00 Stocks Register
The trading price of NuCana plc (NASDAQ:NCNA) closed lower on Monday, March 07, closing at $0.81, -15.35% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7789 and … NuCana plc (NASDAQ: NCNA) Drops -15.35 Percent In Recent Session, Why Are You Interested? Read More »
   The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg  2022/03/06 15:02:06 Benzinga
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB ) retreated in four out of five sessions of the week. Clinical trial updates and FDA-related news moved stocks, while earnings news flow tapered off. NuCana plc. (NASDAQ: NCNA ) was among the worst decliners of the week, with the stock reacting to the stalling of the company''s Phase 3 biliary tract cancer study. SAB Biotherapeutics, Inc. (NASDAQ: SABS ) shares also came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company''s SAB-185 in COVID-19 patients. Celayad Oncology SA (NASDAQ: CYAD ) shares plunged after the company said it is pulling the plug on an early-stage biliary tract cancer study. FDA decisions scheduled for the week were mixed, with Amryt Pharma plc (NASDAQ: AMYT ) and Gilead Sciences, Inc. (NASDAQ: GILD ) failing to get their investigational drugs across the finish line.
   Why Did NuCana Stop Phase 3 Biliary Tract Cancer Trial?  2022/03/03 11:13:10 Benzinga
NuCana plc (NASDAQ: NCNA ) will discontinue its NuTide:121 study following a pre-planned futility analysis by the study''s Independent Data Monitoring Committee (IDMC). The NuTide:121 Phase 3 trial assessed Acelarin plus Cisplatin in patients with previously untreated advanced biliary tract cancer. Although a higher objective response rate was observed in the Acelarin plus cisplatin arm, this
   The Buzz Show: NuCana PLC (NASDAQ: NCNA) FDA Fast Track Designation for Acelarin  2021/09/29 20:22:20 Financial Buzz
FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on NuCana PLC Receives FDA Fast Track Designation for Acelarin NuCana PLC (NASDAQ: NCNA) surged over 26% in premarket trading after the U.S. Food and Drug Administration granted the Fast Track designation to Acelarin. Currently being evaluated in a Phase III study for the first-line The post The Buzz Show: NuCana PLC (NASDAQ: NCNA) FDA Fast Track Designation for Acelarin first appeared on Financial Buzz .
   NuCana PLC (NCNA.Q) Gets Some Good News, Receives Fast Track Designation for Acelarin®  2021/09/29 16:46:45 Equity Guru
NuCana PLC (NCNA.Q) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Acerlarin® (NUC-1031), which is currently being evaluated in a Phase III study (NuTide:121) for the first-line treatment of patients with advanced biliary tract cancer. We are very pleased that the FDA recognizes the potential of Acelarin [] The post NuCana PLC (NCNA.Q) Gets Some Good News, Receives Fast Track Designation for Acelarin® appeared first on Equity.Guru .
   33 Stocks Moving In Wednesday''s Mid-Day Session  2021/09/29 16:09:53 Benzinga
Gainers Paltalk, Inc. (NASDAQ: PALT ) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA ) jumped 31.4% to $3.1150. The FDA granted Fast Track designation to NuCanas Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. Smart Share Global Limited (NASDAQ: EM ) gained 31.4% to $3.77. Smart Share Globals board of directors recently authorized a share repurchase plan for up to $50 million of its shares over the next 12 months. Greenidge Generation Holdings Inc. (NASDAQ: GREE ) shares jumped 28.2% to $30.48. B. Riley Securities initiated coverage on Greenidge Generation with a Buy rating and announced a price target of $78. Neonode Inc. (NASDAQ: NEON ) gained 23.6% to $11.50. Neonode reported that TNB Tech, a Neonode value-added reseller, has been selected by Doostek for contactless airport kiosk trials in South Korea. Camber Energy, Inc. (NYSE: CEI ) gained 23.6% to $3.99. DatChat, Inc. (NASDAQ: DATS ) jumped 18% to $17.24 after jumping over 26% on Tuesday.
   NuCana plc: NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin (NUC-1031) for the Treatment of Biliary Tract Cancer  2021/09/29 12:05:00 FinanzNachrichten
EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NU
   NuCana plc: NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study  2021/09/15 12:05:00 FinanzNachrichten
Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022 Data from First Interim Analysis May Support an NDA Submission in the United States under th
   NuCana plc: NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update  2021/08/19 20:05:00 FinanzNachrichten
EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad cli
   NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update  2021/08/19 20:01:00 Intrado Digital Media
EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
   NuCana plc: NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer  2021/08/10 12:05:00 FinanzNachrichten
Seasoned Physician-Executive Further Strengthens Leadership TeamEDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on signif
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs  2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.

calendar